NCT06001749View on ClinicalTrials.gov

Psilocybin in Cancer Pain Study

PHASE2RecruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Opioid-Related DisordersPain ManagementPain Management and CareAdvanced CancerAdvanced Cancers

Interventions

DRUG

Psilocybin

A tryptamine derivative, capsule, taken orally.

Trial Locations (1)

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Cy Biopharma

UNKNOWN

collaborator

Pancreatic Cancer North America

UNKNOWN

lead

Yvan Beaussant, MD, MSci

OTHER

NCT06001749 - Psilocybin in Cancer Pain Study | Biotech Hunter | Biotech Hunter